In a further effort to elucidate the mechanisms responsible for mediating Rac1 hyperactivation in androgen-independent prostate cancer cells, we performed mass spectrometry with the goal of identifying Rac1 binding partners. The gene discussed is RAC1; the disease is prostate carcinoma.